Invention Grant
- Patent Title: Neurodevelopmental disorder therapy
-
Application No.: US16717921Application Date: 2019-12-17
-
Publication No.: US10888543B2Publication Date: 2021-01-12
- Inventor: Christopher U. Missling
- Applicant: ANAVEX LIFE SCIENCES CORP.
- Applicant Address: US NY New York
- Assignee: ANAVEX LIFE SCIENCES CORP.
- Current Assignee: ANAVEX LIFE SCIENCES CORP.
- Current Assignee Address: US NY New York
- Agency: Polsinelli PC
- Agent Tara A. Nealey
- Main IPC: A61K31/341
- IPC: A61K31/341 ; A61P25/00
Abstract:
This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
Public/Granted literature
- US20200246303A1 Neurodevelopmental Disorder Therapy Public/Granted day:2020-08-06
Information query
